Dexmedetomidine attenuates neuronal injury after stroke ischaemia‐reperfusion injury by targeting REDD1 to reduce excessive autophagy

Authors:
  • HSHaiwei Sun
    Haiwei Sun
  • TYTingting Yu
    Tingting Yu
  • BZBaochun Zhou
    Baochun Zhou
  • JZJianjun Zhu
    Jianjun Zhu
  • QCQingmei Chen
    Qingmei Chen
  • LLLijun Liu
    Lijun Liu

Abstract
Background: Ischemic stroke, accounting for approximately 87% of stroke cases, often leads to severe neurological impairment due to ischemia/reperfusion (I/R) injury. While dexmedetomidine (Dex) has shown potential neuroprotective effects, its precise mechanisms remain unclear. This study investigated whether Dex attenuates cerebral I/R injury by regulating REDD1-mediated autophagy.Methods: Using a rat model of middle cerebral artery occlusion (MCAO) and an in vitro oxygen-glucose deprivation/reoxygenation (OGD/R) model in HT22 cells, we evaluated the effects of Dex on neurological function, infarct volume, and autophagy activity.Results: Dex treatment significantly improved neurological scores, reduced cerebral infarct volume, and ameliorated neuronal damage in MCAO rats. In HT22 cells, Dex enhanced cell viability under OGD/R conditions and suppressed excessive autophagy, as evidenced by decreased LC3-II and increased p62 expression. Mechanistically, Dex upregulated REDD1 expression, and molecular docking confirmed direct binding between Dex and REDD1. HuProt microarray analysis further validated REDD1 as a key target. Crucially, REDD1 knockdown abolished Dex-mediated autophagy inhibition and neuroprotection.Conclusions: These findings demonstrate that Dex alleviates cerebral I/R injury by targeting REDD1 to reduce excessive autophagy, providing novel insights into its therapeutic potential for ischemic stroke.